|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
ophthalmologist
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
gptkb:EMA
2011
|
|
gptkbp:ATCCode
|
S01LA05
|
|
gptkbp:bioavailability
|
local (ocular)
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:blackBoxWarning
|
endophthalmitis risk
|
|
gptkbp:brand
|
gptkb:Eylea
|
|
gptkbp:chemicalClass
|
recombinant fusion protein
|
|
gptkbp:contraindication
|
active intraocular inflammation
ocular infection
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Bayer
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:drugClass
|
anti-VEGF agent
|
|
gptkbp:form
|
injection
solution for injection
|
|
gptkbp:frequency
|
every 4 to 8 weeks
|
|
gptkbp:genericName
|
gptkb:aflibercept
|
|
gptkbp:halfLife
|
~7 days (ocular)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eylea
|
|
gptkbp:indication
|
gptkb:diabetic_macular_edema
gptkb:neovascular_age-related_macular_degeneration
diabetic retinopathy
macular edema following retinal vein occlusion
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
VEGF inhibitor
|
|
gptkbp:molecularWeight
|
115 kDa
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescriptionRequired
|
yes
https://www.eylea.us/
|
|
gptkbp:routeOfAdministration
|
intravitreal injection
|
|
gptkbp:sideEffect
|
glaucoma
conjunctival hemorrhage
eye pain
increased intraocular pressure
vitreous detachment
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:VEGF-A
gptkb:VEGF-B
gptkb:placental_growth_factor_(PlGF)
|
|
gptkbp:bfsParent
|
gptkb:Bayer
gptkb:Lucentis
|
|
gptkbp:bfsLayer
|
5
|